Article | Published:

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination

Nature Structural & Molecular Biology volume 17, pages 12471254 (2010) | Download Citation

Abstract

Inherited mutations in human PALB2 are associated with a predisposition to breast and pancreatic cancers. PALB2′s tumor-suppressing effect is thought to be based on its ability to facilitate BRCA2′s function in homologous recombination. However, the biochemical properties of PALB2 are unknown. Here we show that human PALB2 binds DNA, preferentially D-loop structures, and directly interacts with the RAD51 recombinase to stimulate strand invasion, a vital step of homologous recombination. This stimulation occurs through reinforcing biochemical mechanisms, as PALB2 alleviates inhibition by RPA and stabilizes the RAD51 filament. Moreover, PALB2 can function synergistically with a BRCA2 chimera (termed piccolo, or piBRCA2) to further promote strand invasion. Finally, we show that PALB2-deficient cells are sensitive to PARP inhibitors. Our studies provide the first biochemical insights into PALB2′s function with piBRCA2 as a mediator of homologous recombination in DNA double-strand break repair.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Cancer statistics, 2009. CA-Cancer J. Clin. 59, 225–249 (2009).

  2. 2.

    & The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864–5874 (2006).

  3. 3.

    Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. 4, 461–487 (2009).

  4. 4.

    Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell Biol. 4, 435–445 (2003).

  5. 5.

    et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell 7, 273–282 (2001).

  6. 6.

    et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434, 598–604 (2005).

  7. 7.

    , , , & Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat. Struct. Mol. Biol. 14, 468–474 (2007).

  8. 8.

    et al. The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 136, 1032–1043 (2009).

  9. 9.

    et al. Human CtIP promotes DNA end resection. Nature 450, 509–514 (2007).

  10. 10.

    , , , & Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair. Proc. Natl. Acad. Sci. USA 105, 16906–16911 (2008).

  11. 11.

    & DNA end resection: many nucleases make light work. DNA Repair (Amst.) 8, 983–995 (2009).

  12. 12.

    et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37–45 (2006).

  13. 13.

    , , , & The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature 433, 653–657 (2005).

  14. 14.

    et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719–729 (2006).

  15. 15.

    , & PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. USA 106, 7155–7160 (2009).

  16. 16.

    et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr. Biol. 19, 524–529 (2009).

  17. 17.

    , , & PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res. 7, 1110–1118 (2009).

  18. 18.

    et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165–167 (2007).

  19. 19.

    et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc. Natl. Acad. Sci. USA 104, 6788–6793 (2007).

  20. 20.

    et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39, 162–164 (2007).

  21. 21.

    et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39, 159–161 (2007).

  22. 22.

    et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).

  23. 23.

    et al. Stimulation of fission yeast and mouse Hop2-Mnd1 of the Dmc1 and Rad51 recombinases. Nucleic Acids Res. 35, 2719–2733 (2007).

  24. 24.

    et al. Reconstitution of the strand invasion step of double-strand break repair using human Rad51 Rad52 and RPA proteins. J. Mol. Biol. 304, 151–164 (2000).

  25. 25.

    et al. Interplay between human DNA repair proteins at a unique double-strand break in vivo. EMBO J. 25, 222–231 (2006).

  26. 26.

    , , , & DNA double-stranded breaks induce histone H2AX phosphorylation on serine-139. J. Biol. Chem. 273, 5858–5868 (1998).

  27. 27.

    , , & Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905–916 (1999).

  28. 28.

    et al. Genomic instability in mice lacking histone H2AX. Science 296, 922–927 (2002).

  29. 29.

    Mediating repair. Nat. Struct. Mol. Biol. 12, 213–214 (2005).

  30. 30.

    et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl. Acad. Sci. USA 103, 8768–8773 (2006).

  31. 31.

    et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).

  32. 32.

    et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

  33. 33.

    et al. Enhancement of the RAD51 recombinase by the tumor suppressor PALB2. Nature Struct. Mol. Biol. advance online publication, doi:10.1038/nsmb.1916 (26 September 2010).

  34. 34.

    , , & PALB2 regulates recombinational repair through chromatin association and oligomerization. J. Biol. Chem. 284, 18302–18310 (2009).

  35. 35.

    et al. Functional significance of the Rad51-Srs2 complex in Rad51 presynaptic filament disruption. Nucleic Acids Res. 37, 6754–6764 (2009).

  36. 36.

    , , & Novel pro- and anti-recombination activities of the Bloom's syndrome helicase. Genes Dev. 21, 3085–3094 (2007).

  37. 37.

    et al. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev. 21, 3073–3084 (2007).

  38. 38.

    , , , & Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep. 10, 990–996 (2009).

  39. 39.

    , & D-loop formation by Brh2 protein of Ustilago maydis. Proc. Natl. Acad. Sci. USA 105, 524–529 (2008).

  40. 40.

    , , & CeBRC-2 stimulates D-loop formation by RAD-51 and promotes DNA single-strand annealing. J. Mol. Biol. 361, 231–242 (2006).

  41. 41.

    et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420, 287–293 (2002).

  42. 42.

    , , , & Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med. 11, 456–463 (2005).

  43. 43.

    et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).

  44. 44.

    et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).

  45. 45.

    , , & Purification of human Rad51 protein by selective spermidine precipitation. Mutat. Res. DNA Repair 384, 65–72 (1997).

  46. 46.

    , & Recombinant replication protein A: Expression, complex formation, and functional characterization. J. Biol. Chem. 269, 11121–11132 (1994).

Download references

Acknowledgements

We thank E. Dray, P. Sung, S. Richard, I. Brodeur, E. Paquet, M. Tishkowitz and J. Vignard for helpful discussions, G. Hamel for technical help and I. Brodeur, J. Birraux and A. Rodrigue for critical reading of the manuscript. R.B. is supported by a doctoral scholarship from Le Fonds Québécois de la Recherche sur la Nature et les Technologies. This work was supported by funds from the Swiss National Science Foundation (grant 3103A-116275 to A.S.), the Cancer Institute of New Jersey (B.X.), the US National Cancer Institute (R01CA138804 to B.X.) and the Cancer Research Society (J.-Y.M.). B.X. is an American Cancer Society Research Scholar, and J.-Y.M. is a Fonds de la Recherche en Santé du Québec Senior II investigator.

Author information

Affiliations

  1. Genome Stability Laboratory, Laval University Cancer Research Center, Hôtel-Dieu de Québec, Quebec City, Quebec, Canada.

    • Rémi Buisson
    • , Anne-Marie Dion-Côté
    • , Yan Coulombe
    • , Hélène Launay
    •  & Jean-Yves Masson
  2. Department of Radiation Oncology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

    • Hong Cai
    •  & Bing Xia
  3. Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.

    • Alicja Z Stasiak
    •  & Andrzej Stasiak

Authors

  1. Search for Rémi Buisson in:

  2. Search for Anne-Marie Dion-Côté in:

  3. Search for Yan Coulombe in:

  4. Search for Hélène Launay in:

  5. Search for Hong Cai in:

  6. Search for Alicja Z Stasiak in:

  7. Search for Andrzej Stasiak in:

  8. Search for Bing Xia in:

  9. Search for Jean-Yves Masson in:

Contributions

R.B., A.-M.D.-C., Y.C., H.L., H.C., A.S. and A.Z.S. conceived and carried out experiments. A.S. and B.X. contributed expertise. R.B. conceived the figures. J.-Y.M. provided guidance throughout and wrote the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Jean-Yves Masson.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–7, Supplementary Table 1 and Supplementary Methods

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nsmb.1915

Further reading